Loading organizations...
§ Private Profile · Cambridge, Cambridgeshire, United Kingdom
Biotech company develops fully human monoclonal antibody therapeutics using its Kymouse platform, focused on oncology, infectious diseases, and.
Kymab is a biotechnology company based in Cambridge, United Kingdom, specializing in the development of fully human monoclonal antibody therapeutics utilizing its proprietary Kymouse platform, which expresses the full diversity of human antibody genes. The company successfully raised over $320 million in equity funding, including a $100 million Series C round in 2014, to advance its pipeline for oncology, infectious diseases, and hematological disorders. Key investors and partners supporting its discovery efforts included the Wellcome Trust, Bill & Melinda Gates Foundation, and Woodford. Under leadership from CEOs like David Chiswell and Christian Groendahl, Kymab's innovative platform led to its acquisition by Sanofi in 2022 for an upfront payment of $1.1 billion, plus $350 million in potential milestones, notably for an ICOS-agonist antibody for cancer. Kymab was founded in 2009 by Allan Bradley.
Kymab has raised $229.9M across 5 funding rounds.
Kymab has raised $229.9M in total across 5 funding rounds.
Kymab has raised $229.9M in total across 5 funding rounds.
Kymab's investors include Melanie Lee, Bill & Melinda Gates Foundation, Simone Song, CF Woodford Equity Income Fund, Malin Corporation, Shenzhen Hepalink Pharmaceutical, Woodford Patient Capital Trust, Adrian Howd.
Kymab has raised $229.9M across 5 funding rounds. Most recently, it raised $30.0M Other Equity in June 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 24, 2019 | $30M Venture Round | Melanie LEE | — | Announced |
| Jan 10, 2017 | $9M Grant | Bill & Melinda Gates Foundation | — | Announced |
| Nov 24, 2016 | $100.9M Series C | Simone Song | Bill & Melinda Gates Foundation, CF Woodford Equity Income Fund, Malin Corporation, Shenzhen Hepalink Pharmaceutical, Woodford Patient Capital Trust | Announced |
| May 6, 2015 | $50M Series B Plus | Adrian Howd, Woodford Patient Capital Trust | — | Announced |
| May 16, 2014 | $40M Series B | Bill & Melinda Gates Foundation | — | Announced |